The 22 most recent market catalysts affecting $PFE, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 22, 2026
Corporate Catalyst
Bearish
Impact 55
Trump's Drug Price Achievements Questioned Following Separate Most Favored Nation Contract Disclosures with Lilly, Pfizer
Public Citizen, through a FOIA request, has brought to light redacted 'Most Favored Nation' drug pricing agreements signed by the Trump administration with pharmaceutical giants li…
Sep 18, 2026
Macro/Central Bank
Neutral
Impact 75
White House Official Says Trump To Announce All 50 States, DC, And Puerto Rico In Model For Medicaid Drug Pricing Plan
The filing indicates a forthcoming announcement from the Trump administration regarding a new model for Medicaid drug pricing, which will be implemented across all states and terri…
Sep 8, 2026
Corporate Catalyst
Neutral
Impact 55
'FDA’s Acting Drug, Vaccine Regulators Tapped for Permanent Roles'- Bloomberg
The Bloomberg article reports that the FDA's acting drug and vaccine regulators are being considered for permanent roles. This development signals a potential for stability and con…
Aug 31, 2026
Macro/Central Bank
Bullish
Impact 75
Trump Administration Reaches New Drug Pricing Agreement With Nine Pharma Firms
The White House announced a deal with nine pharmaceutical manufacturers to lower drug prices, a significant development in the ongoing debate over healthcare costs. This agreement …
Aug 28, 2026
Corporate Catalyst
Neutral
Impact 55
CNBC Halftime Report Final Trades: Pfizer, Nvidia, Take-Two Interactive Software, Cheniere Energy
The 'CNBC Halftime Report Final Trades' segment often generates short-term trading interest in the featured stocks. While not based on fundamental news or macro shifts, the exposur…
Aug 28, 2026
Geopolitical Risk
Neutral
Impact 55
World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency
The WHO's decision to maintain the Ebola outbreak in the DRC as a PHEIC, but not elevate it to a pandemic emergency, signifies that while the situation is serious and requires inte…
Aug 19, 2026
Corporate Catalyst
Neutral
Impact 55
President Trump Nominates Heidi Overton, MD, PhD, As Next FDA Commissioner
The filing is a social media post from Donald Trump announcing his intention to nominate Heidi Overton as the next FDA Commissioner. This matters because the FDA Commissioner plays…
Aug 18, 2026
Corporate Catalyst
Neutral
Impact 65
'Trump Is Interviewing Potential Nominees for FDA Commissioner' - Bloomberg
The filing, a Bloomberg article, reports that Donald Trump is interviewing potential nominees for FDA Commissioner. This matters because the FDA plays a critical role in drug appro…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 85
Pfizer And Valneva's Lyme Disease Vaccine Candidate PF-07307405 Clears EMA Validation Of Marketing Authorization Application After Phase 3 VALOR Trial Showed More Than 70% Efficacy
The EMA validation of the marketing authorization application for PF-07307405 is a crucial regulatory hurdle cleared, bringing Pfizer and Valneva significantly closer to commercial…
Aug 10, 2026
Geopolitical Risk
Neutral
Impact 65
Trump Says Administration Recognizing Childhood Vaccine Recommendations For Only 11 Core Vaccinations; Hepatitis B, COVID-19, Influenza No Longer Recommended For All Children
Donald Trump, in a video linked in the filing, stated that a future administration under his leadership would limit recommended childhood vaccinations to 11 core types, specificall…
Aug 6, 2026
Geopolitical Risk
Neutral
Impact 75
'Trump Administration Considers Order on Autism and Vaccines' - Bloomberg
The Bloomberg article indicates that the Trump administration is contemplating an executive order concerning autism and vaccines. This is a significant development because any offi…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 85
Pfizer Says Monthly GLP-1 Candidate Could Rival Tirzepatide on Weight Loss
Pfizer's Q2 results exceeded analyst expectations for both earnings and revenue, primarily due to strong performance from its non-COVID product portfolio. This positive financial u…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 85
Dow Jumps Over 700 Points; Pfizer Posts Upbeat Q2 Earnings
Pfizer's strong Q2 earnings, beating both EPS and revenue estimates, served as a significant positive catalyst for the market. This upbeat corporate performance likely instilled in…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 75
Pfizer Q2 Adj. EPS $0.77 Beats $0.69 Estimate, Sales $15.034B Beat $14.412B Estimate
Pfizer announced its Q2 earnings, revealing adjusted EPS of $0.77 and sales of $15.034 billion, both exceeding analyst expectations. This performance is significant as it demonstra…
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 65
Pfizer Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
The filing details analyst expectations for Pfizer's Q2 earnings, projecting a decrease in both EPS and revenue compared to the prior year. This suggests a challenging quarter for …
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 75
Pfizer Announces Topline Results From Two Phase 3 Trials Of LITFULO In Patients With Vitiligo; Both The 50 And 100 Milligram Doses Delivered Significant, Clinically Meaningful Improvements Over Placebo
Pfizer has disclosed successful Phase 3 trial results for LITFULO in treating nonsegmental vitiligo (NSV), showing significant improvements in facial and total body repigmentation.…
Jul 27, 2026
Corporate Catalyst
Bearish
Impact 55
GOP Congressman Slams JD Vance's Silence Over CDC's $1.24 Billion Pfizer COVID Vaccine Contracts: 'Why Isn’t He Speaking Out'
The filing centers on Rep. Massie's questioning of Vice President Vance's silence regarding the CDC's $1.24 billion contracts with Pfizer for COVID-19 vaccines, given Vance's prior…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 75
FDA Grants Priority Review For Pfizer's Talzenna sNDA For Men With Homologous Recombination Repair Gene-Altered Metastatic Castration-Sensitive Prostate Cancer
The FDA's Priority Review designation for Pfizer's Talzenna sNDA is a significant positive catalyst for Pfizer, indicating the agency believes the drug could offer a substantial im…
Jul 20, 2026
Corporate Catalyst
Bearish
Impact 55
Pfizer Suspends Popular Menopause Cream in India
Pfizer (PFE) has paused the distribution of its Premarin vaginal cream in India, citing unspecified supply chain issues. This is a significant event for the Indian market, as Prema…
Jul 14, 2026
Corporate Catalyst
Neutral
Impact 95
FDA Approves Gedatolisib With Fulvestrant, With Or Without Palbociclib, For Hr-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer
The FDA's approval of Gedatolisib represents a significant development in the treatment of HR-positive, HER2-negative breast cancer. This new therapy, likely from a major pharmaceu…
Jul 13, 2026
Corporate Catalyst
Bearish
Impact 55
BMO Capital Maintains Outperform on Pfizer, Lowers Price Target to $30
BMO Capital's decision to lower Pfizer's price target from $34 to $30, while maintaining an 'Outperform' rating, signals a nuanced view. This adjustment likely reflects updated fin…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.